TCL Archive Paul Marks To Retire As President, CEO Of Memorial Sloan-Kettering Cancer Center December 11, 1998
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive FDA Moves To Revoke Avastin’s Breast Cancer Accelerated Approval, Genentech Vows To Fight December 17, 2010
TCL Archive NCCN’s First Physician CEO: Robert Carlson Pledges Broader Research and Policy Agenda October 5, 2012
